Reneuron Share Discussion Threads

[hlp_4u] 16/2/2016 09:12

Our CTXcryo product, US patents just applied, for could be a major factor in commercialising the breakthrough outlined in the Mirror...hopefully Woodford will have our management knocking on their door.

[small crow] 16/2/2016 09:11

Similar in what way?

[hlp_4u] 16/2/2016 09:08

Front page of the Mirror today....immunotherapy breakthrough... 94 percent cure rate using technology similar to RENE

[aim_trader] 10/2/2016 20:33

ReNeuron CFO Michael Hunt will be presenting to investors at the Proactive One2One Forum in Manchester on the evening of 24th February 2016. To register to attend, please click here:

[ftangftang] 08/2/2016 23:18

link



cheers
ft ft

[stewart_25] 08/2/2016 20:00

what is mentioned - link won't work

[verger] 04/2/2016 14:06

The article has been out for over a month. Very interesting. I guess RENE won't want to shout about it until all patents etc are in place.

[hutch_pod] 04/2/2016 10:45

Wouldn't that mean the Non Exec Chairman knew about this when he purchased shares on the 2nd Feb?

[stewart_25] 04/2/2016 10:30

That is some profound statement by Keith Muir and if substantiated should move the share price massively. IMHO!

[fredd1eboy] 03/2/2016 15:43

A snippet from a recent quote from Professor Keith Muir (principle investigator pisces trials Ren001) article in the lancet... Reneuron yet to report.....

The need for better treatment for this substantial group of severely affected patients has been answered CONCLUSIVELY AND DRAMATICALLY over the past 12 months by a series of landmark clinical trials that will shape the future of acute stroke care and stroke services worldwide.

[stewart_25] 03/2/2016 08:47

1 February 2016 AIM: RENE


ReNeuron Group plc

ReNeuron receives notice of grant of key US patent on its cell cryopreservation technology

Guildford, UK, 1 February 2016: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office for a key patent application covering its cell cryopreservation technology.

The patent application, "Cellular Compositions for use in Therapy" (No. 13/132,475), contains broad claims relating to cryopreserved neural, retinal and mesenchymal stem cells using a formulation developed by ReNeuron researchers that, uniquely, is free of toxic cryopreservants.

ReNeuron has deployed its cryopreservation technology to its lead CTX stem cell line to derive a cryopreserved, long shelf life cell therapy candidate, designated CTXcryo. The Company has received regulatory approval to use CTXcryo, with a current six-month shelf life, in its ongoing UK clinical trials in both stroke disability and critical limb ischaemia.

ReNeuron believes that its patented CTXcryo product will provide the Company with significant commercial and competitive advantages in terms of the availability of a genuine off-the-shelf, low cost-of-goods cell therapy candidate with a shelf life enabling shipping to, and storage at, clinical sites on a global basis.

Equivalent patents to the allowed US patent have already issued in Europe, Japan and Australia.

ReNeuron has broad and multi-layered patent protection covering all of its cell-based technologies and therapeutic candidates. The Company owns or has exclusively licensed more than 80 issued patents, providing protection for its technologies in key potential markets across the globe.

Olav Hellebø, Chief Executive Officer of ReNeuron, said:

"The US Notice of Allowance for our cell cryopreservation technology is an important further addition to ReNeuron's extensive patent estate. We have invested heavily in patents over the years, an investment that we believe will provide significant returns for the Company as our technologies and therapeutic candidates approach commercialisation."

[aim_trader] 02/2/2016 12:33

ReNeuron CFO Michael Hunt will be presenting to investors at the Proactive One2One forum on the evening of the 18th February in London. To register to attend, please click here:

[fredd1eboy] 30/1/2016 10:56

Excellent find by mol on iii site. Looks like good news it's on its way. Final para says it all. Best wishes. Freddie
..................


from K Muir

hxxp://www.researchgate.net/profile/Keith_Muir/publications

this in particular

hxxp://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2815%2900337-3/abstract

Patients with acute ischaemic stroke caused by large artery occlusions, those affecting the terminal parts of the internal carotid artery and the main stem of the middle cerebral artery, have long been recognised to have poor outcomes despite optimum medical care; this is true even when intravenous thrombolysis is used, with up to 25% of patients dying and about 50% left with permanent disability. The need for better treatment for this substantial group of severely affected patients has been answered conclusively and dramatically over the past 12 months by a series of landmark clinical trials that will shape the future of acute stroke care and stroke services worldwide.

we will see if relevant to us - full articles not available as yet - unless registered

[dickbush] 15/1/2016 14:34

Boring is pretty good these days. We're not far from a bear market being called (20% off its peak).

[alimo] 13/1/2016 23:03

We continually get positive news supply and yet the share price takes a dive. You'd think today would have seen a jump up to add to the recent gains, but we get marked down!

[dickbush] 12/1/2016 08:27

A good news update on the potentially most rewarding product line. It remains, of course, the furthest away from development. Still nice to see a bit of unexpected news. Wake me up if it gets to the Lancet.

[small crow] 12/1/2016 07:21

Fascinating stuff - if it makes it to the clinic it could be huge although I am as aware as anyone else that many promising processes fail long before that....

[ftangftang] 12/1/2016 07:14

RNS

Dr John Sinden, Chief Scientific Officer of ReNeuron, said:

"This paper demonstrates the unique characteristic of our CTX cells to preferentially enrich a set of microRNAs contained within their exosomes, which we have shown to have anti-cancer properties in pre-clinical models. The paper therefore represents a significant milestone in ReNeuron's ongoing research to harness the potential of exosomes derived from its proprietary stem cell lines as therapeutics in their own right and also as a system for delivering therapeutic genes."

cheers
ft ft

[rocket fuel] 11/1/2016 15:26

A couple of extra million in the pot that will feed the rene cash burn furnace for one month!

Short term fair value here sub 2p.

Ultimately zero pence to shareholders, but any IP value will live on with founders and city friends and a new name above the door of a private bio tech company.

[stewart_25] 11/1/2016 08:53

Great news - shame its only one click up...

[norbus] 11/1/2016 08:49

RF

Come on, this is heading the right way; maybe 5p in sight

[peawacks] 11/1/2016 08:31

Now that RNS sounds very good. Very good indeed.

[bobdown2] 11/1/2016 08:21

The funding is a validation of a product and the funding to make it work. Does it improve the companies prospects...of course it does.....hey. Someone needed to post!

[bobdown2] 11/1/2016 08:08

Non placing funds...life blood!